company background image
VRTX logo

Vertex Pharmaceuticals NasdaqGS:VRTX Stock Report

Last Price

US$397.27

Market Cap

US$102.3b

7D

-14.3%

1Y

-2.0%

Updated

22 Dec, 2024

Data

Company Financials +

Vertex Pharmaceuticals Incorporated

NasdaqGS:VRTX Stock Report

Market Cap: US$102.3b

VRTX Stock Overview

A biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). More details

VRTX fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Community Narratives

Create a narrative

Narratives bring a range of perspectives from our community.

US$515.27
FV
22.9% undervalued intrinsic discount
8.74%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
18users have followed this narrative
3 days ago author updated this narrative

Vertex Pharmaceuticals Incorporated Competitors

Price History & Performance

Summary of share price highs, lows and changes for Vertex Pharmaceuticals
Historical stock prices
Current Share PriceUS$397.27
52 Week HighUS$519.88
52 Week LowUS$377.85
Beta0.37
1 Month Change-11.91%
3 Month Change-13.64%
1 Year Change-1.97%
3 Year Change77.79%
5 Year Change79.78%
Change since IPO8,728.22%

Recent News & Updates

Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy

Dec 11

Vertex Pharma: Why I Am Buying This Dip

Nov 25

Recent updates

Vertex Pharmaceuticals: Progress Check Suggests Stock Remains A Solid Buy

Dec 11

Vertex Pharma: Why I Am Buying This Dip

Nov 25

Vertex Pharmaceuticals: Strong Execution Continued In Q3 But The Valuation Reflects It

Nov 05

Vertex Pharmaceuticals: The Future Looks Bright, But It May Be A Choppy Ride

Oct 18

Vertex Joined The M&A Craze - Limited Upside Potential (Downgrade)

Oct 10

Investors Are Underestimating The Potential Of Vertex's Non-Addictive Pain Drug

Sep 15

Vertex Pharmaceuticals: Is The Recent Barclays Downgrade Justified? I'm Not Convinced

Sep 05

Vertex Stock: Came For CF Drugs, Staying For Gene Therapy

Aug 02

Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?

Jul 11
Is There An Opportunity With Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) 28% Undervaluation?

Vertex: Strategic Diversification From Gene Therapy To Acute Pain Management

Jul 09

If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Jun 20
If EPS Growth Is Important To You, Vertex Pharmaceuticals (NASDAQ:VRTX) Presents An Opportunity

Vertex: New, Longer-Term Casgevy Data Makes Case For Blockbuster Sales

Jun 17

Vertex: Like A Fine Wine, This Stock Seems To Get Better With Time

Jun 04

Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet

May 09
Here's Why Shareholders Will Not Be Complaining About Vertex Pharmaceuticals Incorporated's (NASDAQ:VRTX) CEO Pay Packet

Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

May 08
Vertex Pharmaceuticals Incorporated Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions

Vertex To Buy Alpine Immune - Why This Deal Feels Slightly 'Vanilla'

Apr 11

Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Apr 05
Getting In Cheap On Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Is Unlikely

Vertex Pharmaceuticals: Diversifying Its Drug Portfolio For Future Growth

Mar 21

Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Mar 15
Are Investors Undervaluing Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) By 35%?

Vertex: One Of My All-Time Favorite Biotech Stocks Has More Room To Run

Feb 28

We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Feb 22
We Like The Quality Of Vertex Pharmaceuticals' (NASDAQ:VRTX) Earnings

Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Feb 07
Earnings Update: Here's Why Analysts Just Lifted Their Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Price Target To US$452

Vertex And Crispr: Second Casgevy Approval Pushes Revenue Potential Into Multi-Billion Dollar Range

Jan 22

With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Jan 15
With EPS Growth And More, Vertex Pharmaceuticals (NASDAQ:VRTX) Makes An Interesting Case

Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Dec 25
Risks To Shareholder Returns Are Elevated At These Prices For Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Shareholder Returns

VRTXUS BiotechsUS Market
7D-14.3%-3.6%-2.4%
1Y-2.0%-2.6%23.4%

Return vs Industry: VRTX matched the US Biotechs industry which returned -2.6% over the past year.

Return vs Market: VRTX underperformed the US Market which returned 23.4% over the past year.

Price Volatility

Is VRTX's price volatile compared to industry and market?
VRTX volatility
VRTX Average Weekly Movement5.0%
Biotechs Industry Average Movement10.8%
Market Average Movement6.3%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: VRTX has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: VRTX's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19895,400Reshma Kewalramaniwww.vrtx.com

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company’s pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial.

Vertex Pharmaceuticals Incorporated Fundamentals Summary

How do Vertex Pharmaceuticals's earnings and revenue compare to its market cap?
VRTX fundamental statistics
Market capUS$102.31b
Earnings (TTM)-US$479.80m
Revenue (TTM)US$10.63b

9.6x

P/S Ratio

-213.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
VRTX income statement (TTM)
RevenueUS$10.63b
Cost of RevenueUS$4.93b
Gross ProfitUS$5.69b
Other ExpensesUS$6.17b
Earnings-US$479.80m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.86
Gross Margin53.59%
Net Profit Margin-4.52%
Debt/Equity Ratio0%

How did VRTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:28
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Vertex Pharmaceuticals Incorporated is covered by 77 analysts. 33 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jasper HellwegArgus Research Company
Brian SkorneyBaird
Ishan MajumdarBaptista Research